Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9568616 | 0.95 | MAPT (0.66) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL9632939 | 0.93 | MCHR1 (0.67) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL16114005 | 0.93 | MCHR1 (0.67) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL18691791 | 0.93 | MCHR1 (0.67) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL10647335 | 0.93 | MCHR1 (0.67) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL2484526 | 0.91 | MAPT (0.66) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL19733316 | 0.87 | MCHR1 (0.58) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL2485359 | 0.85 | RAB9A (0.75) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL30982342 | 0.84 | RAB9A (0.71) | MAPTKDM4ELMNARAB9ANPC1 | |
| SCHEMBL10460812 | 0.84 | RAB9A (0.71) | MAPTKDM4ELMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100376604-C | Olefin polymerization catalyst and its uses | CHINA PETROLEUM & CHEMICAL (CN) | 2008-03-26 | — | — | CN | claimed |
| CN-1769307-A | Olefin polymerization catalyst and its uses | CHINA PETROLEUM & CHEMICAL (CN) | 2006-05-10 | — | — | CN | claimed |
| WO-2017094872-A1 | ULTRAVIOLET ABSORBER | 国立大学法人大阪大学 | 2017-06-08 | — | — | WO | disclosed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| CN-100376604-C | Olefin polymerization catalyst and its uses | CHINA PETROLEUM & CHEMICAL (CN) | 2008-03-26 | — | — | CN | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| CN-1769307-A | Olefin polymerization catalyst and its uses | CHINA PETROLEUM & CHEMICAL (CN) | 2006-05-10 | — | — | CN | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0435687-B1 | Process for isomerization of oxime ethers | SUMITOMO CHEMICAL CO (JP) | 1995-03-29 | — | — | EP | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0428351-B1 | Synthesis of quinoline and substituted quinoline copolymers | EXXON RESEARCH ENGINEERING CO (US) | 1994-12-21 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5162495-A | Contacting tetrahydroquinoline compound with a quinoline compound in presence of metal sulfide catalyst | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| US-5130486-A | A ketoximine ether isomerized using a Lewis acid metal halide | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1992-07-14 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0435687-A2 | Process for isomerization of oxime ethers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-07-03 | — | — | EP | disclosed |
| EP-0428351-A2 | Synthesis of quinoline and substituted quinoline copolymers | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4031215-A | STREPTOMYCES, ALDOL CONDENSATION | KAKEN CHEMICAL CO., LTD. (JA) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | MAPT 2869/4885KDM4E 2150/4885LMNA 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.